Company Overview

Moolec Science SA (Nasdaq: MLEC) is a science-based food ingredient company focused on producing animal proteins and nutritional compounds through molecular farming, a biotechnology approach that uses genetically engineered plants to express proteins traditionally sourced from animals. The company operates within the biotechnology, food technology, and alternative protein industries, targeting the growing market for sustainable food ingredients and next-generation agricultural production systems. Its primary commercial focus has centered on producing ingredients such as bovine proteins, nutritional oils, and specialty compounds in crops including soybeans and peas.

The company’s strategy is built around combining agricultural production with biotechnology to lower production costs and improve scalability relative to conventional fermentation or livestock-based protein systems. Moolec originated from biotechnology initiatives associated with the Bioceres ecosystem in Latin America and later became a publicly traded company through a business combination involving a special purpose acquisition company. The company has positioned itself at the intersection of food security, climate-focused agriculture, and synthetic biology by integrating crop science with ingredient manufacturing.

Business Operations

Moolec Science generates value primarily through the development and commercialization of genetically engineered crops designed to express high-value proteins and food ingredients. Its operating activities include research and development, intellectual property generation, seed and trait development, regulatory approvals, and commercialization partnerships. The company has focused on molecular farming platforms capable of embedding functional proteins directly into crops, potentially reducing downstream processing requirements and manufacturing costs.

The company’s operations have included activities across South America, North America, and parts of Europe, with research collaborations and agricultural production partnerships supporting field development and regulatory advancement. Moolec has maintained ties within the broader Bioceres Group ecosystem and has worked with biotechnology, agricultural, and ingredient-sector partners to advance commercialization. Its core assets include proprietary genetic engineering technologies, crop trait platforms, and intellectual property related to protein expression in plants.

Strategic Position & Investments

Moolec Science’s strategic direction centers on scaling molecular farming as a commercially viable alternative to traditional animal protein and precision fermentation systems. The company has emphasized growth through research partnerships, regulatory approvals, and expansion of its proprietary crop portfolio. Key development programs have included soybean-based production systems for bovine proteins and pea-based platforms for specialty nutritional ingredients. The company has also explored opportunities in functional food ingredients and sustainable protein supply chains.

The company has pursued strategic acquisitions and business combinations intended to broaden its biotechnology capabilities and public-market access. Its positioning is differentiated by its attempt to integrate agricultural scalability with biotechnology-driven ingredient production, rather than relying solely on industrial fermentation infrastructure. Moolec has also been associated with emerging sectors including alternative proteins, climate-resilient agriculture, and synthetic biology-enabled food manufacturing. Some commercial deployment timelines and scale assumptions remain dependent on regulatory approvals and market adoption, and certain forward-looking commercialization targets are subject to uncertainty based on available public disclosures.

Geographic Footprint

Moolec Science maintains an international operating profile with connections to agricultural and biotechnology markets across Latin America, North America, and Europe. The company has corporate and operational ties to the agricultural biotechnology ecosystem developed in Argentina, while also maintaining a public-market presence in the United States through its Nasdaq listing. Its activities have included field trials, research collaborations, and commercialization planning across multiple jurisdictions.

The company’s business model relies on access to major agricultural production regions capable of supporting large-scale crop cultivation. As a result, its strategic footprint has emphasized regions with strong soybean and pea production infrastructure, biotechnology research capabilities, and supportive agricultural innovation frameworks. Regulatory engagement in multiple international markets remains an important component of its expansion strategy.

Leadership & Governance

Moolec Science leadership has included executives with backgrounds in biotechnology, agribusiness, food innovation, and capital markets. The company’s governance structure reflects its origins within the broader agricultural biotechnology sector and its transition into a publicly traded biotechnology enterprise. Leadership messaging has consistently emphasized sustainable food production, scalable biotechnology, and the integration of agriculture with molecular biology to address future protein demand.

Key executives and directors have included:

• Gaston Paladini – Co-Founder and Chief Executive Officer
• Martin Salinas – Chief Financial Officer
• Matias Correa – Chief Science Officer
• Federico Trucco – Chairman of the Board
• Miguel Calzada Alvarez – Director

Public disclosures indicate that management’s strategic vision has focused on developing commercially scalable molecular farming platforms capable of competing with conventional animal protein supply chains on both cost and sustainability metrics. Some executive and board composition details may change over time based on corporate filings and governance updates.